Jim Cramer on Merck & Co., Inc. (MRK): ‘Drug Stocks Are Really Getting Hurt’
We recently published an article titled Jim Cramer Discusses These 10 Stocks & An Outfit Better Than DeepSeek. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands ...
FiercePharma3d
UPDATE: Merck KGaA sets its sights on acquisition of Ogsiveo maker SpringWorks
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
China leaves Merck in need of a new profit injection
Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...
BioPharma Dive2d
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...
STAT9d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
BioSpace2d
SpringWorks Wins FDA Nod for Neurofibromatosis Drug, Tees Up Challenge to AstraZeneca
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
What Investors Are Missing about Pfizer and Merck
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Why Merck Stock Is Plummeting Today
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...